We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

News · September 29, 2020

ESMO 2020: ASCENT Positions Sacituzumab Govitecan as Possible Standard of Care for Previously Treated Metastatic Triple-Negative Breast Cancer

This first-in-class agent is currently being evaluated in other settings

ESMO Press Commentary


Further Reading